Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, and its filings offer detailed insight into financial performance, clinical milestones and strategic developments around its WAKIX (pitolisant) franchise and late-stage CNS pipeline.
Recent Forms 8-K filed by Harmony Biosciences report preliminary and actual financial results, such as net product revenue for WAKIX, multi-quarter revenue growth and updated annual guidance ranges. These filings also incorporate press releases and investor presentations that describe the company’s status as a profitable, self-funding biotech with a robust late-stage pipeline, as well as disclosures tied to participation in major healthcare conferences. For investors analyzing HRMY, these documents help contextualize revenue trends, cash generation and spending on research and development, sales and marketing, and general and administrative activities.
Harmony’s 8-K filings also reference significant clinical and regulatory events, including topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome, preannounced WAKIX performance, and updates on Phase 3 and Phase 1 programs such as pitolisant GR, pitolisant HD, EPX-100, EPX-200 and BP1.15205. Through these filings, readers can follow how clinical outcomes, trial initiations and program decisions feed into the company’s overall strategy in sleep–wake disorders, rare epilepsies and neurobehavioral conditions.
On Stock Titan, Harmony Biosciences’ SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, including 8-Ks and, when available, 10-K annual reports, 10-Q quarterly reports and proxy materials. Investors can also monitor insider and executive transaction reports on Form 4 and other ownership filings as they appear in the EDGAR feed. This combination of real-time updates and AI-generated explanations helps users quickly understand the implications of HRMY’s regulatory disclosures without reading every page of each filing.
Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 144 reporting a proposed sale of 21,573 common shares, representing restricted stock units acquired on 03/29/2023. The sale is to be executed through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $787,630.23 and an indicated approximate sale date of 08/15/2025. The filing shows 57,532,601 shares outstanding and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information and discloses the sale is related to previously granted RSUs.